Home  /  Resource Library  /  Quality of Life Impact of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

Quality of Life Impact of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

Results of a phase III study comparing Mogamulizumab with Vorinostat on impact on quality of life in patients with cutaneous t-cell lymphoma.